| [Fire Fighting] Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire. | |
| [Ingestion] Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended. | |
| [Inhalation] If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention. | |
| [Skin] Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes. | |
| [Eyes] If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention. | |
| [Storage] Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage. | |
| [Handling] All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood. | |
| [Inhalation] Increased airway resistance, wheezing, pulmonary edema, cyanosis, respiratory depression may develop. In severe cases respiratory arrest may occur. | |
| [Eyes] Diplopia and eye irritation may develop with therapeutic use. Mydriasis has been reported overdose. | |
| [Ingestion] Nausea and vomiting may be noted. Mesenteric ischemia has been reported as a sequelae of overdose. | |
| [Personal Protection] Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots. | |
| [Respirators] Use NIOSH/MSHA approved respirator appropriate for exposure of concern. | |
| [Exposure Effects] Low heart rate and abnormally low blood pressure are common. Respiratory depression may occur with severe poisoning. fatigue, sleepiness, headache, sedation and confusion may develop with therapeutic use. CNS depression, coma and seizures may develop in overdose. | |
| [Appearance] White crystalline powder. | |
| [Solubility in water] very soluble | |
| [pKa/pKb] 9.68 (pKa) | |
| [Usage] Ay be useful for treatment of angina pectoris, hypertension, or cardiac arrhythmias. | |
| [Product Name] 1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol (2:1) Dextro-tartrate salt | |
| [Synonyms] 1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol (2:1) dextro tartrate salt 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) CGP 2175 lopressor Metoproferm | |
| [CAS] "CASEN_56392-17-7.htm">56392-17-7 | |
| [Formula] C34H56N2O12 | |
| [Molecular Weight] 342.41 | |
| [EINECS] 260-148-9 | |
| [RTECS] UB7450100 | |
| [RTECS Class] Drug; Reproductive Effector; Human Data | |
| [Beilstein/Gmelin] 4088731 | |
| [Small spills/leaks] Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces. | |
| [Stability] No data. | |
| [Incompatibilities] Strong oxidizing agents. |
Print